Benchmark lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $67 and keeps a Buy rating on the shares after the company announced worse than expected Q3 results and lowered revenue guidance for the remainder of 2024. The firm, which thinks the stock still deserves to be at a premium to the comp group average “despite the current rough patch,” would be buyers on weakness.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $67 from $82 at Stifel
- Exact Sciences price target lowered to $65 from $82 at BTIG
- Exact Sciences price target lowered to $82 from $90 at TD Cowen
- Exact Sciences price target lowered to $67 from $70 at Baird
- Exact Sciences price target lowered to $75 from $88 at BofA